AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Most species of lancelet are known to produce GFP in various regions of their body. Unlike A. victoria, lancelets do not produce their own blue light, and the origin of their endogenous GFP is still unknown. Some speculate that it attracts plankton towards the mouth of the lancelet, serving as a passive hunting mechanism. It may also serve as a photoprotective agent in the larvae, preventing damage caused by high-intensity blue light by converting it into lower-intensity green light. However, these theories have not been tested. GFP-like proteins have been found in multiple species of marine copepods, particularly from the Pontellidae and Aetideidae families. GFP isolated from Pontella mimocerami has shown high levels of brightness with a quantum yield of 0.92, making them nearly two-fold brighter than the commonly used EGFP isolated from A. victoria.
SELDI technology was developed by T. William Hutchens and Tai-Tung Yip at Baylor College of Medicine in 1993. Hutchens and Yip attached single-stranded DNA to agarose beads and used the beads to capture lactoferrin, an iron-binding glycoprotein, from preterm infant urine. The beads were incubated in the sample and then removed, washed, and analyzed with a MALDI-MS probe tip. This research led to the idea that MALDI surfaces could be derivatized with SEAC devices; the technique was later described by Hutchens and Yip in 1998. SELDI technology was first commercialized by Ciphergen Biosystems in 1997 as the ProteinChip system, and is now produced and marketed by Bio-Rad Laboratories.
The ionic radius is expected to decrease regularly for Mn2+ to Zn2+. This would be the normal periodic trend and would account for the general increase in stability. The crystal field stabilisation energy (CFSE) increases from zero for manganese(II) to a maximum at nickel(II). This makes the complexes increasingly stable. CFSE returns to zero for zinc(II). Although the CFSE for copper(II) is less than for nickel(II), octahedral copper(II) complexes are subject to the Jahn–Teller effect which results in a complex having extra stability. Another example of the effect of ionic radius the steady increase in stability of complexes with a given ligand along the series of trivalent lanthanide ions, an effect of the well-known lanthanide contraction.
{\displaystyle h=C{{\left[{\frac {k_{v}^{3}{{\rho }_{v}}g\left({{\rho }_{L}}-{{\rho }_{v}}\right)\left({{h}_{fg}}+0.4{{c}_{pv}}\left({{T}_{s}}-{{T}_{sat}}\right)\right)}{{{D}_{o}}{{\mu }_{v}}\left({{T}_{s}}-{{T}_{sat}}\right)}}\right]}^{{}^{1}\!\!\diagup \!\!{}_{4}\;}}}
Sources: en.wikipedia.org
== Background == The origin of the armed conflict in Colombia goes back to 1920, with agrarian disputes over the Sumapaz and Tequendama regions. Much of the background of the Colombian conflict is rooted in La Violencia, a conflict in which liberal and leftist parties united against the dictator of Colombia, Gustavo Rojas Pinilla. At the time, Colombia was a banana republic dominated by foreign monopolies, specifically the United Fruit Company. The United Fruit Company existed to buy large quantities of agricultural products in Latin America at cheap prices, then resell the crops in foreign markets for inflated amounts. Local farmers were impoverished and forced to grow specific crops, creating a monoculture in which farmers depended on the company for all food, products, and wages. The United Fruit Company would usually pay its workers in coupons that were worthless outside company stores, which would further charge extravagant prices compared to what workers earned. Further, the employment system was usually one in which farmers would be forced to sell their property to the United Fruit Company. They ended up having to work on the land, becoming indebted to the company and having to pay it back. The United Fruit Company would hire private militaries to enforce its power. Their purpose was to put down worker calls for reform, destroy unions, and put down worker revolutions. Any potential government threat to the United Fruit Company's interests in the country would result in its overturning in a company-backed coup.
== Divisions == Roche has two major divisions: Pharmaceuticals and Diagnostics. Roche Diagnostics manufactures diagnostic equipment and reagents for research and medical diagnostic applications. Internally, it is organised into five major business areas: Roche Applied Science, Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics and Roche Tissue Diagnostics (Ventana). The main location for Roche Professional Diagnostics is in Rotkreuz, Switzerland. All business areas except Roche Applied Science focus on health care applications, targeting either physicians, hospitals and clinics, or consumers. Applied Science targets research settings in academia and pharmaceutical and biotechnology industries.
== Techniques == Techniques commonly used in the field of phytochemistry are extraction, isolation, and structural elucidation (MS,1D and 2D NMR) of natural products, as well as various chromatography techniques (MPLC, HPLC, and LC-MS).
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.